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Abstract—The purpose of this study was to assess the concentration of C-reactive protein (CRP) in
obese type 2 diabetes mellitus (DM2) patients and its association with macrovascular and microvas-
cular complications. The study group consisted of 80 obese DM2 patients, including 20 macrovasc-
ular, 20 microvascular, 20 both macrovascular and microvascular, and 20 with no complications
patients. The control group comprised 40 normoglycemic subjects—20 obese and 20 of normal body
weight. Highly sensitive CRP and metabolic control parameters were assessed. CRP levels in obese
diabetes subgroups and normoglycemic obese were similar and signiﬁcantly higher than those in
nonobese controls. No correlation was found between CRP and diabetes control parameters. There
was a strong positive correlation between CRP level and body mass index in all groups. A multivariate
analysis showed that DM2 and obesity are independent factors increasing CRP levels. Increased
concentration of CRP in obese DM2 patients is related to obesity and diabetes itself. The lack of
association between CRP and vascular complications remains unclear.
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INTRODUCTION
Obesity and type 2 diabetes mellitus (DM2) are
considered to be associated with a low-grade inﬂammation,
which may play a signiﬁcant role in the development of
cardiovascular complications [1, 2]. C-reactive protein
(CRP) is an extremely sensitive marker of systemic
inﬂammation produced mainly by the liver under the
stimulation of adipocyte-derived proinﬂammatory cytokines
[3]. CRP has also emerged as a powerful predictor of
cardiovascular diseases [4]. Elevated levels of CRP are
described in DM2 subjects; however, it is not clear if they
are related to the presence of obesity, diabetes, or both [5–9].
Some studies indicate a relationship between CRP and
macrovascular complications of diabetes [10–14]. It has not
yet been shown whether the CRP level increases due to the
metabolic effects of obesity and diabetes and plays a direct
role in promoting the inﬂammatory component of athero-
sclerosis or whether it is merely a marker of the ongoing
inﬂammation in the vessels affected by diabetes [15, 16].
Data on elevated CRP levels in diabetic patients with
nephropathy or retinopathy providing a link between
inﬂammation and the development of microvascular com-
plications are very scarce [17–21]. None of the performed
studies conducted in DM2 patients examined CRP levels in
connection with both macro- and microangiopathy. The
purpose of this study was to evaluate the concentration of
CRP in obese patients with long-standing DM2 (>10 years)
and its association with the presence of diabetes
macrovascular and microvascular complications.
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The study group consisted of 80 obese individuals
(46 men and 34 women) aged 43–82 years (65.1±
8.6 years) with DM2 of 10–35 years of duration (16.4±
5.6 years), with a body mass index (BMI) of 30.0–
49.7 kg/m2 (34.0±3.7 kg/m2), and treated with diet and/or
oral hypoglycemic drugs and/or insulin. The study group
was constituted in such a way as to include 20 subjects
with macrovascular complications (MA), 20 subjects
with microvascular complications (MI), 20 subjects with
macrovascular and microvascular complications (MA +
MI), and 20 patients without chronic organ complications
of diabetes (COMP (−)). The MA group consisted of 20
patients with ischemic heart disease; in 4 of them, chronic
limb ischemia was found. In the MI group, retinopathy
was present in 11 subjects (9 with simplex retinopathy
and 2 with preproliferative retinopathy associated with
maculopathy), nephropathy in 12 (11 deﬁned by
increased albuminuria and 1 by proteinuria), and
neuropathy in 7. The MA + MI group included 20
patients diagnosed ischemic heart disease with chronic
limb ischemia in 6 and history of stroke in 2 of them;
coexisting microangiopathy in this group was as follows:
11 subjects—presence of simplex retinopathy (2 cases
associated with maculopathy), 12—presence of
nephropathy (10 deﬁned by increased albuminuria and 2
by overt proteinuria), and 11—neuropathy.
The control group DM (−) comprised 40 persons,
including 20 obese subjects (15 women and 5 men) aged
40–76 years (57.0±9.5 years), with BMI of 30.3–44.8 kg/
m2 (37.0±4.3 kg/m2), and 20 subjects with normal body
weight (lean) (16 women and 4 men) aged 40–67 years
(54.3±6.5 years), with BMI of 19.3–24.8 kg/m2 (22.6±
1.4 kg/m2). In both groups, carbohydrate metabolism
disorders were excluded by means of an oral glucose
tolerance test (75 g). Persons with a diagnosis of ischemic
heart disease, atherosclerosis, and occlusive arterial
disease, those after stroke, and those with suspected
ischemic heart disease on the basis of their medical
history and/or standard ECG were not included in the
control group. The study was performed after approval by
the Ethics Committee of the Pomeranian Medical
University in Szczecin, Poland.
Methods
After giving informed written consent to participate
in the study, each subject was inquired about age, diabetes
duration, coexisting diseases (hypertension, ischemic
heart disease, coronary artery disease, lipid disorders,
stroke), and therapy, including the use of drugs modifying
the CRP blood concentration (thiazolidinediones, statins,
ﬁbrates, hormone replacement therapy (HRT)) and
stimulants (cigarettes, alcohol). All subjects underwent
physical examination and measurement of BMI and
waist/hip ratio (WHR).
The diagnosis of ischemic heart disease was based on
a medical history of stenocardial pain, myocardial infarc-
tion, previous tests used in diagnosing ischemic heart
disease, and ischemic changes detected in the standard
electrocardiogram. If necessary, additional tests, such as
treadmill stress testing, cardiac ultrasound, and angiogra-
phy, were performed. The presence of atherosclerosis of
the lower extremities was assessed on the basis of a history
of claudication and the measurement of pulse in the lower
limb arteries. Cerebral atherosclerosis was diagnosed on
the basis of a history of dizziness and previous stroke and
by carotid auscultation. Additional tests, such as carotid
Doppler ultrasound, Doppler ultrasound of the lower limb
arteries, and angiography, were performed if necessary.
Diabetic retinopathy was diagnosed by fundoscopic
examination by an ophthalmologist. The presence of
diabetic nephropathy was evaluated on the basis of
proteinuria present in urinalysis or diurnal urinary
albumin excretion rate (UAER) ≥30 mg/24 h (measured
twice). The diagnosis of diabetic neuropathy was based
on detailed clinical assessment including diabetic neu-
ropathy symptoms (typical neuropathic pain, orthostatic
hypotension), loss of vibration perception with a 128-Hz
tuning fork (scale value <6/8), or loss of sensation found
with a 10-g Semmes–Weinstein monoﬁlament examina-
tion. Both mentioned tests were performed in all patients.
Subjects were not included in the study if there was an
increased serum creatinine level and a suspicion of
inﬂammation, cancer, or other diseases likely to affect
the CRP level on the basis of their medical history, physical
examination, and additional laboratory tests, such as blood
count, erythrocyte sedimentation rate (ESR), or urinalysis.
The levels of fasting plasma glucose (FPG); total, LDL,
and HDL cholesterol; triglycerides; CRP; and glycated
hemoglobin A1c (HbA1c) were measured, and 24-h blood
pressure monitoring (SpaceLabs 9027) was conducted in
all subjects.
Laboratory Tests
Glucose concentration was determined by an enzy-
matic method (Cormay kit with hexokinase, PZ Cormay
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SA, Poland). Cholesterol and triglycerides were deter-
mined by an enzymatic colorimetric method (COBAS
INTEGRA kit, Roche, Switzerland). The concentration
of CRP was evaluated by immunonephelometry
(CardioPhase* hsCRP set, Dade Behring, Germany).
HbA1c was determined by high-pressure liquid chroma-
tography (HPLC; Variant™ HemoglobinA1c, BIO-RAD,
USA). Creatinine concentration was determined with the
Jaffe method (COBAS INTEGRA kit, Roche, Switzer-
land). Urinalysis was performed using test strips (Lab
U11 Strip Plus Analyticon, Germany). Albuminuria was
determined by the immunoradiometric assay (Albumin
RIA kit, Immunotech, Czech Republic). Leukocytosis
was evaluated using a Pentra DX 120 analyzer (Horiba
ABX Diagnostics, Japan). ESR was determined by
sedimentation (Westergren method).
Statistical Analysis
The relationships between nominal variables (e.g.,
gender) were analyzed using the chi-square test or with
Fisher's exact test for dichotomous variables. All mea-
surable variables (e.g., CRP) were assessed for normal
distribution with the Shapiro–Wilk test. In case of normal
distribution, the means of the measurable variables were
compared across groups with the use of Student's t test
and in case of deviation from the normal distribution, with
the use of nonparametric tests. In the latter case, in order
to compare the values of variables between the two
groups, the Mann–Whitney U test was used, and in case
of a larger number of compared groups, the ANOVA
Kruskal–Wallis test was used. The relationship between
two measurable variables was analyzed with Spearman's
rank correlation coefﬁcient (Rs). Variables with normal
distribution were described as mean±standard deviation
(SD). Variables with distributions signiﬁcantly deviating
from normal (where p for the Shapiro–Wilk test was below
0.05 and the SDwas higher than the average) were described
as median (interquartile range). Multivariate analysis was
based on the linear regression model. The threshold p value
for statistical signiﬁcance was set to p<0.05. The analysis
was performed using Statistica 6.1 Pl.
RESULTS
Group Comparison
The characteristics of patients in the studied sub-
groups are summarized in Table 1. The 24-h blood
pressure, heart rate, and laboratory test results are shown
in Table 2.
CRP Concentrations in the Studied Subgroups
CRP concentration in the group of obese DM2
patients was 0.22 mg/dL (0.02–1.26) and did not differ
signiﬁcantly from that in the group of obese subjects
without diabetes: 0.13 mg/dL (0.04–0.74). There were no
differences between CRP concentrations in different
subgroups of the DM2 group (Fig. 1). In the subgroup
with macrovascular complications, they measured
0.19 mg/dL (0.09–0.89), in the subgroup with microvas-
cular complications 0.24 mg/dL (0.03–1.13), in the
subgroup with both macrovascular and microvascular
complications 0.21 mg/dL (0.03–1.26), and in the
subgroup without chronic vascular complications
0.25 mg/dL (0.02–0.94). The above CRP concentrations
were not different from those observed in the obese
controls, while they were signiﬁcantly higher when
compared to those in the normal body weight subjects:
0.07 mg/dL (0.02–0.75, p<0.01).
The Relationship Between Serum CRP Concentration
and the Studied Parameters
There was a positive correlation between CRP
concentration and BMI in the obese subjects with DM2
(Rs=0.36, p=0.001), obese without diabetes (Rs=0.56,
p=0.012), and those with normal body weight without
diabetes (Rs=0.52, p=0.028), but with no correlation
with WHR (Fig. 2). A very strong correlation between
CRP and BMI was observed in DM2 subjects without
vascular complications (Rs=0.79, p<0.0001), but was not
present in subgroups with different diabetic complica-
tions and was not related to patients' age, duration of
diabetes, hypertension, or cigarette smoking.
The relationships between CRP and the parameters
analyzed in the different subgroups of the study group are
summarized in Table 3. The subgroup with macrovascular
complications of diabetes showed a positive correlation
between CRP and HbA1c levels, and the subgroup with
macrovascular and microvascular complications showed
a negative correlation between CRP and FPG. There was
no statistically signiﬁcant correlation between CRP
concentration and the parameters analyzed in the sub-
group with microvascular complications. A positive
correlation between CRP and total cholesterol, and ESR
was observed in the subgroup of patients without chronic
vascular complications of diabetes.
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A multivariate analysis of the cumulative effect of
age, gender, BMI, and presence of diabetes on the
concentration of CRP was carried out, and the resulting
linear model (R2=0.25) showed that both BMI (Beta=
0.52, p<0.000001) and the presence of diabetes (Beta=
0.26, p=0.011) are signiﬁcant independent factors
affecting the CRP level.
DISCUSSION
The present study compared the concentration of
CRP in obese DM2 patients, obese without diabetes, and
normal body weight subjects without diabetes and
assessed the relationship between CRP concentration
and the presence of macrovascular and microvascular
complications, and glycemic control. The selection of the
study group was not random. Chronic inﬂammation plays
a speciﬁc role in people with DM2 and coexisting obesity.
The sources of inﬂammatory cytokines that modulate
inﬂammatory reactions in these patients are both immune
cells, activated by hyperglycemia and associated meta-
bolic disorders, and adipocytes. The study group was split
into four subgroups according to vascular complications
in order to assess the relationship between inﬂammatory
markers and the presence of diabetes complications. The
purpose of the two control groups: obese and normal body
weight nondiabetic patients, was to enable the assessment
of the extent to which CRP is determined by the presence
of diabetes and obesity itself.
The very clear relationship that we observed
between CRP concentration and BMI in obese DM2
patients, as well as in the group of obese people without
diabetes and normal-weight subjects without diabetes,
conﬁrms the role of adipose tissue in initiating and
sustaining inﬂammation. Signiﬁcantly higher CRP levels
in obese subjects, both diabetic and nondiabetic, vs. those
in slim individuals, as well as a strong positive correlation
between CRP and ESR values in obese subjects, both
diabetic and nondiabetic, which was not observed in
normal body weight persons, suggest that obesity is a
state corresponding to subminimal inﬂammation. It
should be emphasized that in all patients included in the
study, the presence of any medical condition with features
of inﬂammation was excluded, and ESR and leukocyte
count were within normal limits. These results are
consistent with data reported by other authors [5, 22–26].
It is surprising that despite the very clear relationship
between CRP and BMI, there was no relationship
between CRP and WHR ratio, which is an indicator of
visceral obesity since, according to current knowledge,
the principal place of production of inﬂammatory
cytokines and proteins is visceral tissue [27, 28].
However, it is worth remembering that in order to directly
determine the amount of visceral fat, it is necessary to use
radiological techniques (CT, MRI), which would allow to
distinguish the two types of abdominal fat: visceral and
subcutaneous [29]. In addition, recent reports suggest that
apart from visceral tissue, the perivascular adipose tissue,
surrounding almost all blood vessels, may also be a
source of inﬂammatory cytokines [30]. In the present
Table 1. Characteristics of Patients in Studied Subgroups
Parameter
DM2 DM (−)
MA n=20 MI n=20 MA + MI n=20 COMP (−) n=20 OBESE n=20 LEAN n=20
Age (years) 67.0±7.5 60.7±10.3 ~ - 67.6±6.7 63.1±7.3 ~ - 57.0±9.5 ~~ – * 54.3±6.5 ~~ – **
Duration of DM (years) 16.9±7.0 15.7±4.6 19.0±5.5* 14.2±3.9 – –
Sex (F/M) 14/6 11/9 9/11 12/8 15/5 16/4
BMI (kg/m2) 33.1±2.8 34.7±5.2 34.0±2.7 34.2±3.6 37.0±4.3 ~~ - 22.6±1.4 ~~ ++ – ** ^^
WHR 0.92±0.07 0.94±0.07 0.95±0.06 0.92±0.06 0.90±0.07 - 0.82±0.07 ~~ ++ – ** ^^
Hypertension (n) 20 18 20 15 ~ - 12 ~ - 2 ~~ ++ – ** ^
Smoking (n) 0 5 1 1 2 6
Alcohol abuse (n) 0 0 0 0 0 0
HRT (n) 3 0 0 1 0 0
Statins (n) 11 5 12 3 ~ - 1 ~ - 0 ~ + -
Fibrates (n) 2 1 0 0 0 0
PPAR-γ agonists (n) 0 0 0 0 0 0
~p<0.05, ~~p<0.001 vs. MA; +p<0.05, ++p<0.001 vs. MI; -p<0.05, –p<0.001 vs. MA+MI; *p<0.05, **p<0.001 vs. COMP (−); ^p<0.05,
^^p<0.001 vs. OBESE
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study, CRP levels in obese diabetic and nondiabetic
subjects did not differ signiﬁcantly. Since the obese
nondiabetic group was characterized by signiﬁcantly
higher BMI in comparison to obese patients with DM2,
with a strong relationship between CRP and BMI, one
could have expected that the CRP concentration in the
group of obese nondiabetic subjects would be higher than
that in obese diabetic patients. Contrary to expectations,
CRP levels were, in fact, slightly lower in that group. The
explanation may be the presence of diabetes itself; as
shown in the multivariate analysis, DM2 is an indepen-
dent factor increasing the value of CRP. It thus seems that
elevated CRP levels in subjects with DM2 and obesity are
the result of the simultaneous impact of obesity and
diabetes. The mechanism of the effect of diabetes on the
CRP concentration remains unclear, even more so since
there was no correlation between CRP and glycemic
control measured by HbA1c and glucose levels. CRP
values also showed no relation to lipid disorders and
hypertension, which accompany diabetes.
The results indicate no relationship between CRP
concentration and diabetic macro- and microangiopathy.
This relationship certainly does not exist for microvascu-
lar complications, which were assessed very precisely. In
the group with evidence of microangiopathy, the CRP
level was 0.24 mg/dL and in subjects with macro- and
microangiopathy 0.21 mg/dL. These values were almost
identical to those observed in patients without microvas-
cular complications (0.25 mg/dL). The results reported by
other authors indicating the existence of such a relation-
ship could be due to the fact that they did not consider
body weight and the presence of obesity in their
assessments [11]. This assumption is conﬁrmed by a
study which showed higher levels of CRP and ﬁbrinogen
in a group with DM2 and microalbuminuria compared to
a group of patients with DM2 and normoalbuminuria, but
in which, this correlation was signiﬁcantly weakened
after adjustment for BMI [18]. In our study, the diagnosis
of diabetic macrovascular disease was not precise, for it
was based largely on physical examination and ECG
while imaging studies (ultrasound, angiography) were
performed only in part of the patients. Therefore, it cannot
be deﬁnitely excluded that among the diabetic patients
assigned to the group with microvascular complications
or to the group without complications, some individuals
with asymptomatic coronary artery disease or other
macroangiopathy could be found. Even if this happened,
subjects with diagnosed macrovascular disease had to
have changes much more advanced compared to those in
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this group than in the others. This delivered arguments against
the concept that CRP is a marker of inﬂammatory changes
associated with the presence of atherosclerosis in the vessels,
as suggested by some authors [11, 31]. The lack of association
between elevated CRP levels and vascular complications
observed in our study remains unclear. It is possible that in the
group of patients with diabetic macroangiopathy (both with




MA MI MA+MI COMP (-) OBESE LEAN












DM 2 DM (-)
*
Fig. 1. Median concentrations of CRP in studied subgroups.




















Fig. 2. The relationship between CRP concentration and BMI in studied subgroups.
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might have been slightly lowered due to drugs used for
treatment of cardiovascular complications. Some of them,
including aspirin, beta-blockers, convertase inhibitors, and
sartans, have been shown to lower theCRP concentration [32,
33]. Statins, which can also have such an effect [34], were
used with similar frequency in the groups of patients with
different complications.
The present study showed no relationship between
CRP and the degree of glycemic control, as assessed by
the level of HbA1c. Similar results were obtained by the
authors of other studies [5, 23, 25]. However, there are
counter-reports indicating a correlation between in-
creased levels of CRP and worse glycemic control [26,
35, 36]. It cannot be ruled out that this discrepancy of
results may be due to different degrees of metabolic
control since one of the studies showed that the CRP
concentration had a tendency to increase in parallel with
HbA1c, but this relationship was only observed in
patients with HbA1c above 9 % [36]. It should be
emphasized that the group of patients evaluated in our
study presented signiﬁcantly better glycemic control
(HbA1c=7.2 %). The relationship between CRP concen-
Table 3. The Relationship Between CRP Concentration and Parameters Analyzed in Studied Subgroups
Parameter
DM2 DM (−)
MA n=20 MI n=20 MI + MA n=20 COMP (−) n=20 OBESE n=20 LEAN n=20
Data from the medical interview
Age (years) Rs=−0.2 Rs=−0.42 Rs=+0.14 Rs=−0.32 Rs=−0.06 Rs=+0.36
p=0.4 p=0.06 p=0.57 p=0.17 p=0.79 p=0.12
Duration of DM (years) Rs=−0.12 Rs=−0.42 Rs=+0.13 Rs=−0.05 – –
p=0.61 p=0.06 p=0.59 p=0.83
Anthropometric measurements
BMI (kg/m2) Rs=−0.27 Rs=+0.19 Rs=+0.34 Rs=+0.79 Rs=+0.56 Rs=+0.52
p=0.25 p=0.42 p=0.14 p<0.0001 p<0.02 p<0.03
WHR Rs=−0.2 Rs=+0.14 Rs=−0.09 Rs=−0.3 Rs=−0.02 Rs=+0.22
p=0.43 p=0.58 p=0.7 p=0.2 p=0.94 p=0.38
24-h blood pressure and heart rate values
24-h sBP (mm Hg) Rs=−0.18 Rs=+0.09 Rs=+0.33 Rs=−0.16 Rs=−0.07 Rs=+0.16
p=0.45 p=0.71 p=0.15 p=0.51 p=0.76 p=0.51
24-h dBP (mm Hg) Rs=+0.09 Rs=+0.19 Rs=−0.21 Rs=−0.39 Rs=−0.37 Rs=−0.2
p=0.72 p=0.42 p=0.39 p=0.09 p=0.12 p=0.41
24-h HR (t/min) Rs=−0.01 Rs=+0.16 Rs=−0.25 Rs=−0.37 Rs=+0.17 Rs=+0.13
p=0.95 p=0.5 p=0.29 p=0.12 p=0.49 p=0.6
Laboratory tests
Fasting glucose (mg/dL) Rs=+0.01 Rs=−0.11 Rs=−0.49 Rs=−0.16 Rs=−0.23 Rs=+0.06
p=0.96 p=0.63 p=0.03 p=0.51 p=0.33 p=0.8
HbA1c (%) Rs=+0.53 Rs=+0.14 Rs=+0.26 Rs=+0.08 Rs=−0.02 Rs=+0.13
p<0.02 p=0.56 p=0.26 p=0.73 p=0.92 p=0.59
Total cholesterol (mg/dL) Rs=+0.16 Rs=−0.1 Rs=+0.12 Rs=+0.52 Rs=+0.07 Rs=+0.08
p=0.5 p=0.69 p=0.6 p<0.02 p=0.77 p=0.74
LDL cholesterol (mg/dL) Rs=+0.12 Rs=+0.02 Rs=+0.12 Rs=+0.32 Rs=+0.04 Rs=+0.39
p=0.62 p=0.9 p=0.62 p=0.17 p=0.87 p=0.09
HDL cholesterol (mg/dL) Rs=−0.01 Rs=−0.37 Rs=+0.09 Rs=+0.06 Rs=+0.03 Rs=−0.49
p=0.96 p=0.1 p=0.7 p=0.8 p=0.9 p<0.03
Triglycerides (mg/dL) Rs=+0.1 Rs=+0.27 Rs=+0.18 Rs=+0.26 Rs=+0.03 Rs=+0.12
p=0.66 p=0.26 p=0.5 p=0.27 p=0.89 p=0.6
Creatinine (mg/dL) Rs=−0.23 Rs=−0.25 Rs=+0.06 Rs=−0.1 Rs=−0.11 Rs=+0.28
p=0.24 p=0.92 p=0.8 p=0.69 p=0.67 p=0.23
UAER (mg/24 h) Rs=−0.22 Rs=+0.37 Rs=+0.02 Rs=−0.31 Rs=+0.24 Rs=+0.4
p=0.35 p=0.11 p=0.9 p=0.18 p=0.29 p=0.09
ESR (mm/h) Rs=0.39 Rs=+0.34 Rs=+0.4 Rs=+0.59 Rs=+0.73 Rs=+0.26
p=0.14 p=0.19 p=0.11 p<0.02 p<0.001 p=0.29
Leukocytes (G/L) Rs=+0.4 Rs=+0.2 Rs=+0.12 Rs=+0.23 Rs=+0.43 Rs=+0.15
p=0.08 p=0.4 p=0.63 p=0.33 p=0.06 p=0.52
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tration and glycemic control parameters indicated by
some authors can stem from not taking into account the
inﬂuence of BMI on the results obtained. After BMI
values were incorporated into the statistical analysis, the
correlations were importantly disvalued and became
statistically insigniﬁcant [25, 31]. The lack of relationship
between CRP concentration and glycemic control was
also conﬁrmed by a study conducted by Pradhan et al.,
who, having introduced hypoglycemic therapy that
resulted in an improvement of glycemic control, did not
observe a decrease of CRP, IL-6, or TNF-α levels [37].
CONCLUSIONS
The obtained results indicate that the most important
factor determining an increase in the concentration of CRP
in obese DM2 patients is excess body fat and the presence
of diabetes itself, while the vascular complications and the
degree of glycemic control do not show any signiﬁcant
correlation with this inﬂammatory parameter. Further
research is required to elucidate the role of inﬂammation
in the development of diabetic vascular complications.
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